公开(公告)号：US20230248734A1

公开(公告)日：2023-08-10

申请号：US18001333

申请日：2021-06-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Soo Bong HAN ,  Jin Soo SHIN ,  Mee Hyein KIM ,  Eunhye JUNG ,  Ye Jin JANG ,  Hyuk LEE ,  Myoungkyu LEE ,  Dongsu KIM ,  Chang Soo YUN ,  Young Sik JUNG

IPC: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/5091

Abstract: The present invention relates to the development of a composition for the treatment of novel SARS-coronavirus-2 infection. The drug efficacy was evaluated through CPE (Cytopathic Effect)-based assay method that measures how long the cells survive by infecting SARS-CoV-2 after receiving a drug library previously approved as a treatment for a specific disease from the Korea Chemical Bank and treating Vero cells with the drug, and an image-based assay that measures how much virus is reduced in infected cells. Through this, 16 kinds of drugs effective in the treatment of SARS-CoV-2 were re-positioned.